Miriam Mason - Annexon Senior Communications
| ANNX Stock | USD 5.10 0.04 0.78% |
Executive
Miriam Mason is Senior Communications of Annexon
| Address | 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005 |
| Phone | 650 822 5500 |
| Web | https://www.annexonbio.com |
Annexon Management Efficiency
The company has return on total asset (ROA) of (0.2483) % which means that it has lost $0.2483 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.422) %, meaning that it created substantial loss on money invested by shareholders. Annexon's management efficiency ratios could be used to measure how well Annexon manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.47 in 2024. Return On Capital Employed is likely to drop to -0.54 in 2024. At this time, Annexon's Net Tangible Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.3 M in 2024, whereas Total Assets are likely to drop slightly above 209.3 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| William Grossman | Arcus Biosciences | 50 | |
| Debra DursoBumpus | Blueprint Medicines Corp | 54 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Lani Ibarra | Structure Therapeutics American | N/A | |
| Jim Watters | Relay Therapeutics | N/A | |
| Julian Baker | Blueprint Medicines Corp | 57 | |
| Deborah Palestrant | Relay Therapeutics | N/A | |
| David Marks | Immix Biopharma | N/A | |
| Tony Peng | Structure Therapeutics American | N/A | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Camille MD | Amylyx Pharmaceuticals | 71 | |
| Daryn Lewis | Wave Life Sciences | N/A | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Gina JD | Amylyx Pharmaceuticals | 53 | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Michael Howell | Zura Bio Limited | 47 | |
| Yvonne Gehring | Arcus Biosciences | N/A | |
Management Performance
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.25 |
Annexon Leadership Team
Elected by the shareholders, the Annexon's board of directors comprises two types of representatives: Annexon inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Annexon. The board's role is to monitor Annexon's management team and ensure that shareholders' interests are well served. Annexon's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Annexon's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shikhar MBA, Senior Commercial | ||
| Arnon Rosenthal, Founder | ||
| Michael MBA, Executive Officer | ||
| Mirella Toro, Sec | ||
| JD Esq, President CEO | ||
| Ted Yednock, Chief VP | ||
| HenkAndre MD, Senior Medicine | ||
| Jamie MD, Executive Officer | ||
| Esq JD, Pres CEO | ||
| Larry Mattheakis, Ex Officer | ||
| Jennifer Lew, Ex CFO | ||
| Miriam Mason, Senior Communications | ||
| Dean Artis, Chief VP | ||
| Sunil PharmD, Senior Affairs |
Annexon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Annexon a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 237.38 M | ||||
| Shares Outstanding | 106.59 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 99.51 % | ||||
| Number Of Shares Shorted | 7.77 M | ||||
| Price To Book | 1.65 X | ||||
| EBITDA | (141.57 M) | ||||
| Net Income | (134.24 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Annexon Stock Analysis
When running Annexon's price analysis, check to measure Annexon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexon is operating at the current time. Most of Annexon's value examination focuses on studying past and present price action to predict the probability of Annexon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexon's price. Additionally, you may evaluate how the addition of Annexon to your portfolios can decrease your overall portfolio volatility.